Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Receives $44.90 Average PT from Brokerages

Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Get Free Report) have been assigned a consensus rating of “Moderate Buy” from the eleven brokerages that are covering the firm, MarketBeat reports. One research analyst has rated the stock with a hold recommendation and ten have issued a buy recommendation on the company. The average twelve-month target […]

Related Keywords

Canada ,China ,Richard Scott Struthers ,Stephenf Betz ,Highmark Wealth Management ,Crinetics Pharmaceuticals Price Performance ,Royal Bank ,Crinetics Pharmaceuticals Inc ,Jefferies Financial Group ,Institutional Trading Of Crinetics Pharmaceuticals ,China Universal Asset Management Co ,Osaic Holdings Inc ,News Ratings For Crinetics Pharmaceuticals Daily ,Crinetics Pharmaceuticals ,Analyst Recommendations For Crinetics Pharmaceuticals ,Cantor Fitzgerald ,Crinetics Pharmaceuticals Company Profile ,Jpmorgan Chase Co ,Insider Activity At Crinetics Pharmaceuticals ,Nasdaq ,Morgan Stanley ,Securities Exchange Commission ,Tower Research Capital ,Get Free Report ,Financial Group ,Scott Struthers ,Exchange Commission ,Universal Asset Management ,Research Capital ,Mark Wealth Management ,Get Free ,Crinetics Pharmaceuticals Daily ,Nasdaq Crnx ,Crnx ,Medical ,Ratings ,Consensus ,